Selegiline’s neuroprotective capacity revisited

@article{Riederer2003SelegilinesNC,
  title={Selegiline’s neuroprotective capacity revisited},
  author={P. Riederer and L. Lachenmayer},
  journal={Journal of Neural Transmission},
  year={2003},
  volume={110},
  pages={1273-1278}
}
  • P. Riederer, L. Lachenmayer
  • Published 2003
  • Medicine
  • Journal of Neural Transmission
  • 33 Citations

    Tables and Topics from this paper

    Explore Further: Topics Discussed in This Paper

    Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
    • 96
    • Highly Influenced
    • PDF
    MAO-inhibitors in Parkinson's Disease
    • 140
    • PDF
    90 years of monoamine oxidase: some progress and some confusion
    • K. Tipton
    • Medicine
    • Journal of Neural Transmission
    • 2018
    • 25
    Biocatalysis for synthesis of pharmaceuticals.
    • R. Patel
    • Medicine, Chemistry
    • Bioorganic & medicinal chemistry
    • 2018
    • 63

    References

    SHOWING 1-10 OF 36 REFERENCES
    Half-life time for striatal MAO-B recovery is 9,23 days
    • Youdim and Tipton
    • 1994
    necessary to avoid increase of dopamine) reached only 31 hours after enzyme blockade with tranylcypromine. For PEA this value is 70 hours
    • 1977
    Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.
    • 40
    • Highly Influential
    Slow recovery of human brain MAO B after L‐Deprenyl (Selegeline) withdrawal
    • 144
    • Highly Influential
    Symptomatic effect of selegiline in de novo parkinsonian patients
    • 75
    • Highly Influential
    Increased life
    • J Neurochem
    • 1985
    Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study
    • 129
    Die Parkinson-Krankheit. Grundlagen, Klinik, Therapie, 3 edn
    • 2003
    Neuroprotection in Parkinson's disease: Clinical trials
    • 99